Neuraxis director gains shares via stock dividend
Neuraxis (NRXS) director Aharon Gil reported stock awards tied to preferred share dividends rather than open‑market trading.
Rhea-AI Filing Summary
Neuraxis (NRXS) director Aharon Gil reported stock awards tied to preferred share dividends rather than open‑market trading. On April 28, 2026, entities associated with him acquired 221,917 shares of common stock indirectly through Rosalind Master Fund L.P. and 12,304 shares directly.
These shares were issued as dividends on Series B Preferred Stock, calculated by dividing accrued and unpaid 8.5% cumulative dividends by $2.38 per share. Following the transactions, Gil’s reported holdings total 508,055 indirect shares and 33,902 direct shares of Neuraxis common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 234,221 shares
Grant/Award
2 txns
Insider
Aharon Gil
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 12,304 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 221,917 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 33,902 shares (Direct);
Common Stock — 508,055 shares (Indirect, By Rosalind Advisors, Inc., the advisor to the Rosalind Master Fund L.P.)
Footnotes (4)
- F1. Includes (1) 21,598 shares of common stock issued to the Reporting Person as previously disclosed, and (2) 12,304 shares of common stock issued to the Reporting Person as a dividend on the Series B Preferred Stock owned by the Reporting Person.
- F2. Includes (1) 286,138 shares of common stock purchased by Rosalind Master Fund L.P. in which the Reporting Person has indirect ownership as previously disclosed, and (2) 221,917 shares of common stock issued as a dividend on the Series B Preferred Stock owned by Rosalind Master Fund L.P.
- F3. The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.
- F4. Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.
Key Figures
Direct shares acquired: 12,304 shares
Indirect shares acquired: 221,917 shares
Direct holdings after transaction: 33,902 shares
+3 more
6 metrics
Direct shares acquired
12,304 shares
Common stock issued as dividend on Series B Preferred to reporting person
Indirect shares acquired
221,917 shares
Common stock dividend on Series B Preferred to Rosalind Master Fund L.P.
Direct holdings after transaction
33,902 shares
Total Neuraxis common stock held directly following April 28, 2026 awards
Indirect holdings after transaction
508,055 shares
Neuraxis common stock held indirectly via Rosalind Master Fund L.P.
Preferred dividend rate
8.5% cumulative dividends
Rate used to calculate common stock dividends on Series B Preferred Stock
Dividend conversion rate
$2.38 per share
Accrued and unpaid dividends divided by $2.38 to determine common shares
Key Terms
Series B Preferred Stock, 8.5% cumulative dividends, pecuniary interest, indirect ownership, +1 more
5 terms
Series B Preferred Stock financial
"shares of common stock issued as a dividend on the Series B Preferred Stock owned"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
8.5% cumulative dividends financial
"determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock"
pecuniary interest financial
"disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein"
indirect ownership financial
"shares of common stock purchased by Rosalind Master Fund L.P. in which the Reporting Person has indirect ownership"
grant, award, or other acquisition financial
"transaction code description: Grant, award, or other acquisition"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Neuraxis (NRXS) director Aharon Gil report?
Director Aharon Gil reported acquisitions of Neuraxis common stock through stock awards, not market trades. On April 28, 2026, he acquired 221,917 shares indirectly via Rosalind Master Fund L.P. and 12,304 shares directly, all issued as dividends on Series B Preferred Stock.
Were Aharon Gil’s Neuraxis (NRXS) transactions in this Form 4 open-market buys or sells?
No, the Form 4 characterizes both transactions as acquisitions from grants or awards, not open‑market buys or sells. The shares were issued as stock dividends on Series B Preferred Stock, with zero transaction price per share reported, reflecting a non‑cash issuance mechanism.
What dividend terms on Neuraxis (NRXS) Series B Preferred Stock are disclosed in this Form 4?
The Form 4 discloses that Series B Preferred Stock carries 8.5% cumulative dividends. The number of common shares issued as dividends to Rosalind Master Fund L.P. and Aharon Gil was determined by dividing accrued and unpaid dividends by $2.38, yielding 221,917 and 12,304 common shares respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
